Protalix BioTherapeutics — Third Quarter 2026 Earnings Summary

Protalix BioTherapeutics reported total revenues of $75.6 million for the nine months ended September 30, 2026, representing a $32.0 million increase from the same period in 2025. The company achieved a net income of $26.1 million for the nine-month period and $4.0 million for the third quarter, driven primarily by higher sales to partner Chiesi and a $25.0 million milestone payment. Protalix reaffirmed its 2026 revenue guidance of approximately $78.0 million to $83.0 million and maintains a cash position of $48.5 million as of September 30, 2026. Clinical progress includes the ongoing Phase 2 RELEASE study for PRX-115, with top-line results anticipated in the second half of 2027, and the recent marketing authorization of Elfabrio in Brazil.